Chongfan Technology
News
04
2024
-
08
Lancet sub-journal, Guangdong Provincial People's Hospital Wu Yilong and other teams reported for the first time the latest results of terpolitinib combined with oxitinib in the treatment of EGFR mutant non-small cell lung cancer patients!
Author:
Patients with EGFR-mutated non-small cell lung cancer (NSCLC) and MET amplification as mechanisms of first-line osimertinib resistance have few treatment options.
On August 2, 2024, Wu Yilong of Guangdong Provincial People's Hospital and Tae Min Kim of Seoul University of South Korea jointly communicatedLancet Oncology(IF=41.6)Published online entitled“Tepotinib plus osimertinib in patients with EGFR-mutated non-small-cell lung cancer with MET amplification following progression on first-line osimertinib (INSIGHT 2): a multicentre, open-label, phase 2 trial”The research paper,The study conducted aMulticenter, open-label, phase 2 trial of terpolitinib in combination with osimertinib in patients with EGFR-mutated non-small cell lung cancer.
The results of the study show that terportinib combined with osimertinib shows good activity and acceptable safety in patients with EGFR-mutated NSCLC and MET amplification, as a mechanism of first-line osimertinib resistance, which indicates that a potential chemotherapy-sparing oral targeted treatment regimen needs to be further studied.
Terbolitinib is a highly selective oral MET TKI approved for the treatment of advanced or metastatic MET exon 14 skipping NSCLC5 and is recommend as a treatment option for NSCLC with high levels of de novo MET amplification. Due to its high selectivity, terpolitinib shows a low risk of off-target toxicity and can be used in combination with EGFR TKIs. Preclinical and clinical studies have supported the combination of terpolitinib and EGFR TKIs in the treatment of NSCLC with EGFR mutations and Met amplification.Phase 2 INSIGHT trials have shown that for EGFR-mutated, Thr790Met-negative, MET-amplified NSCLC patients, terpolitinib combined with gefitinib has a better clinical benefit than chemotherapy, and the disease of these patients has progressed on previous EGFR TKIs.

Analysis of anti-tumor activity in the main active population
In conclusion, the study shows that terpolitinositinib has a significant impact onEGFRMutated NSCLC patients, whose disease has progressed under first-line osimertinib treatment and who have MET amplification, provide promising clinical benefit and manageable safety.The results of the study indicate that terpolitinositinib is a potential chemotherapy-saving oral targeted treatment option that may help address the high unmet medical need in this situation, as it provides an effective regimen with a manageable safety profile that enables patients to defer any IV treatment burden.
Chongqing Chongfan Technology Co., Ltd. Optical platform film thickness meter OCT optical coherence tomography LabVIEW control
LATEST NEWS
Thank you for visiting the official website of Chongfan Technology. If you have cooperation intentions or suggestions, please contact us through the following methods, and we will reply as soon as possible, thank you!
Address: Room 403, Building 6, Phase III of R&D, No. 36 Xiyong Avenue, High tech Zone, Chongqing, China.
Telephone: +86-13658337211
E-mail: Sales@cfkeji.net
Website: www.cfkeji.net
Mobile Version